Rigel Pharmaceuticals Stock Forecast, Price & News

+0.07 (+1.83 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume5.23 million shs
Average Volume2.69 million shs
Market Capitalization$666.32 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for Rigel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Rigel Pharmaceuticals logo

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.96 out of 5 stars

Medical Sector

608th out of 1,350 stocks

Pharmaceutical Preparations Industry

298th out of 664 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

Is Rigel Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Rigel Pharmaceuticals stock.
View analyst ratings for Rigel Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Rigel Pharmaceuticals?

Wall Street analysts have given Rigel Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rigel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Rigel Pharmaceuticals

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings data on Tuesday, August, 3rd. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. The biotechnology company had revenue of $26.27 million for the quarter, compared to the consensus estimate of $22.08 million. Rigel Pharmaceuticals had a negative trailing twelve-month return on equity of 13.37% and a negative net margin of 5.36%.
View Rigel Pharmaceuticals' earnings history

How has Rigel Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RIGL shares have increased by 115.5% and is now trading at $3.90.
View which stocks have been most impacted by COVID-19

What price target have analysts set for RIGL?

3 equities research analysts have issued 1-year price targets for Rigel Pharmaceuticals' stock. Their forecasts range from $11.00 to $11.00. On average, they expect Rigel Pharmaceuticals' share price to reach $11.00 in the next year. This suggests a possible upside of 182.1% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:
  • Raul R. Rodriguez, President, Chief Executive Officer & Director
  • Dean L. Schorno, Chief Financial Officer & Executive Vice President
  • Wolfgang Dummer, Chief Medical Officer & Executive Vice President
  • David Santos, Chief Commercial Officer & Executive VP
  • Joseph Lasaga, Senior Vice President-Corporate Development

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals CEO Raul Rodriguez on Raul Rodriguez has an approval rating of 84% among Rigel Pharmaceuticals' employees.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.94%), BlackRock Inc. (9.81%), State Street Corp (6.26%), Vanguard Group Inc. (5.31%), Tamarack Advisers LP (3.75%) and Invesco Ltd. (3.02%).
View institutional ownership trends for Rigel Pharmaceuticals

Which major investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, State Street Corp, Dimensional Fund Advisors LP, BlackRock Inc., Panagora Asset Management Inc., Lord Abbett & CO. LLC, Rafferty Asset Management LLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Rigel Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was acquired by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, Nuveen Asset Management LLC, Schonfeld Strategic Advisors LLC, Wells Fargo & Company MN, Goldman Sachs Group Inc., CM Management LLC, and Simplex Trading LLC.
View insider buying and selling activity for Rigel Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $3.90.

How much money does Rigel Pharmaceuticals make?

Rigel Pharmaceuticals has a market capitalization of $666.32 million and generates $108.62 million in revenue each year. The biotechnology company earns $-29,740,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

How many employees does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals employs 169 workers across the globe.

When was Rigel Pharmaceuticals founded?

Rigel Pharmaceuticals was founded in 1996.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is

Where are Rigel Pharmaceuticals' headquarters?

Rigel Pharmaceuticals is headquartered at 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 624-1100 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.